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ABSTRACT: This study reports the results of the combined effect of pH and surfactant
on the dissolution of piroxicam (PX), an ionizable water-insoluble drug in physiological
pH. The intrinsic dissolution rate (Jtotal) of PX was measured in the pH range from 4.0
to 7.8 with 0%, 0.5%, and 2.0% sodium lauryl sulfate (SLS) using the rotating disk
apparatus. Solubility (ctotal) was also measured in the same pH and SLS concentration
ranges. A simple additive model including an ionization (PX ↔ H+ + PX−) and two
micellar solubilization equilibria (PX + micelle ↔ [PX]micelle, PX− + micelle ↔
[PX−]micelle) were considered in the convective diffusion reaction model. Jtotal and ctotal
of PX increased with increasing pH and SLS concentration in an approximately addi-
tive manner. Nonlinear regression analysis showed that observed experimental data
were well described with the proposed model (r2 4 0.86, P < 0.001 for Jtotal and r
2 4
0.98, P < 0.001 for ctotal). The pKa value of 5.63 ± 0.02 estimated from ctotal agreed well
with the reported value. The micellar solubilization equilibrium coefficient for the
unionized drug was estimated to be 348 ± 77 L/mol, while the value for the ionized drug
was nearly equal to zero. The diffusion coefficients of the species PX, PX−, and [PX]mi-
celle were estimated from the experimental results as (0.93 ± 0.35) × 10−5, (1.4 ± 0.30)
× 10−5, and (0.59 ± 0.21) × 10−5 cm2/s, respectively. The total flux enhancement is less
than the total solubility enhancement due to the smaller diffusion coefficients of the
micellar species. This model may be useful in predicting the dissolution of an ionizable
water insoluble drug as a function of pH and surfactant and for establishing in vitro–in
vivo correlations, IVIVC, for maintaining bioequivalence of drug products. © 2000 Wiley-
Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 89: 268–274, 2000
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INTRODUCTION
A Biopharmaceutic Classification System (BCS)
has been recently proposed for drug product bio-
equivalence requirements. Solubility and perme-
ability, the key parameters in BCS, play impor-
tant roles in the development of formulations and
regulatory standards. Particularly for water in-
soluble drugs that have generally high membrane
permeability (BCS Class II), dissolution and dose
are the most critical factors affecting the rate and
the extent of oral absorption.1 It is well known
that dissolution is affected by the environmental
changes in the gastrointestinal tract such as pH,
surfactant, ionic strength, buffer capacity, or vis-
cosity.2
The effect of pH and the effect of surfactant on
the dissolution of drugs have been individually
investigated by many researchers for the past
several decades. Higuchi 3developed a one-dimen-
sional diffusion layer theory describing the
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effect of surfactant on the dissolution of a solid.
Gibaldi et al.4,5examined the influence of polyoxy-
ethylene (23) lauryl ether on the dissolution of
benzoic acid and salicylic acid by the rotating disk
and the static disk method. Singh et al.6 investi-
gated the influence of micelle–drug solubilization
on the dissolution rate for the benzocaine–
polysorbate 80 system under different hydrody-
namic models. De Smidt et al.7–9 reported the ef-
fect of sodium lauryl sulfate on the dissolution of
griseofulvin, a poorly soluble drug. On the other
hand, Mooney et al.10,11 investigated the effect of
pH on the solubility and dissolution of ionizable
drugs based on a film model with total component
material balances for reactive species, proposed
by Olander.12 McNamara and Amidon 13,14devel-
oped a convective diffusion model that included
the effects of ionization at the solid–liquid surface
and irreversible reaction of the dissolved species
in the hydrodynamic boundary layer. However,
there is very little attention paid to the combined
effect of pH and micellar solubilization.
The objective of this paper is to investigate the
combined effect of pH and surfactant on the in-
trinsic dissolution rate of an ionizable water in-
soluble drug. Piroxicam (PX, Figure 1) was chosen
as the model drug. The intrinsic dissolution and
solubility of PX were measured in buffer solutions
at various pH values and different concentrations
of sodium lauryl sulfate (SLS) using the rotating
disk dissolution method. A major question to be
answered by these studies is whether additivity of
pH and surfactant solubilization can account for
the experimental results.
THEORETICAL SECTION
Micelle Facilitated Dissolution Influenced by pH
Model
Both pH and surfactant often affect the dissolu-
tion of an ionizable water insoluble drug. Figure 2
illustrates a proposed model describing equilibria
of PX in aqueous solution containing a surfac-
tant.2 This scheme includes an ionization equilib-
rium and two solubilization equilibria. PX−,
[PX]micelle, and [PX
−]micellar represent ionized
drug, unionized drug in micelle, and ionized drug
in the micelle, respectively. It is reported that PX
can be ionized as a zwitterion which has two pKa
values (pKa1 4 1.86, pKa2 4 5.46 measured in
DMSO–buffer 1:100).15 However, the pKa1 value
is relatively low compared with the biological pH
range of the small intestine. Therefore, PX was
treated as a weak acid not an ampholyte in this
paper. The equilibrium constant for the ionization
is defined as follows:
Ka 4 (cPX−)[H
+]/cPX (1)
where [H+] is hydrogen ion concentration, and cPX
and cPX
− are the concentrations of unionized and
ionized drugs, respectively. The following equilib-
ria between free solute and micelle solubilized
solute are assumed16–19:
k* 4 c[PX]micelle/{(cPX)(cm)} (2)
k** 4 c[PX−]micelle/{(cPX−)(cm)} (3)
cm 4 csurfactant − cmc (4)
Figure 2. Equilibrium scheme of PX in surfactant so-
lution.
Figure 1. Structure of PX.
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where k* and k** are the equilibrium constants
for micellar solubilization of unionized and ion-
ized species, cm is the concentration of surfactant/
micelle which is equal to surfactant concentration
(csurfactant) minus critical micelle concentration
(cmc 4 0.008 M for SLS),17,20 c[PX]micelle and
c[PX−]micelle are the concentrations of unionized
and ionized drugs in the micelle, respectively.
Total Solubility
The combined effect of pH and surfactant on the
solubility of weakly acidic and basic drugs was
discussed by Rippie et al.16 The total solubility
(ctotal) of a weak acid in surfactant solution can be
expressed as a sum of the solubility values of each
species:
ctotal 4 cPX + cPX− + c[PX]micelle + c[PX−]micelle (5)
Substituting cPX−, c[PX]micelle, and c[PX−]micelle in eq
5 using eqs 1, 2, and 3 gives eq 6:
ctotal 4 {1 + Ka/[H
+]
+ (k* + k**Ka/[H
+])cm}cPX (6)
Dissolution
The general equation describing the mass trans-
port in a fluid is21
­ci/­t 4 Di=
2ci − n=ci + Ri (7)
where Di, ci, and Ri are the diffusion coefficient,
the molar concentration, and the rate of produc-
tion per volume of species i, n is the fluid velocity,
and t is time. The terms on the right side of eq 7
represent the diffusive, convective, and reactive
contributions to mass transfer, respectively. As-
suming the instantaneous irreversible reactions
at the solid–liquid surface, mass transfer in the




2 − nzdci /dz 4 0 (8)
where nz is the axial velocity of fluid toward the
disk. Levich22solved the equation to derive the
flux of the solute from the rotating disk as
J 4 0.62Di
2/3 v−1/6v1/2ci0 (9)
where J is the flux, v is the kinematic viscosity, Di
is the diffusivity, ci0 is the concentration of spe-
cies i at the disk surface, and v is the angular
velocity of the disk. Equation 9 can be applied to
the micelle-facilitated dissolution of an ionizable
drug from the rotating disk to give
Jtotal 4 0.62Deff
2/3v−1/6v1/2ctotal (10)
where Jtotal is the total flux of the drug and Deff is
the effective diffusivity. The total dissolution rate
(Jtotal) is expressed as:
Jtotal 4 JPX + JPX− + J[PX]micelle
+ J[PX−]micelle (11)












Substituting JPX, JPX− , J[PX]micelle, and J[PX−]micelle











for the total flux.
The experimental data will be evaluated for
agreement with eq 6 for solubility and eq 16 for
dissolution.
EXPERIMENTAL SECTION
Materials and Data Analysis
Piroxicam (PX) and sodium lauryl sulfate (SLS,
>99% purity) were purchased from Sigma Chemi-
cal Company (St. Louis, MO). Distilled, deionized,
and filtered water was used for all experiments. A
stainless steel rotating disk with a tablet radius
of 0.55 cm was used for dissolution experiments.
Model fitting and parameter estimations were
performed with nonlinear regression analysis by
SigmaPlot (SPSS Inc., Chicago, IL). The regres-
sion analysis for the dissolution data was
weighted by reciprocal values of square of the
standard deviation.
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Dissolution Media
McIlvaine buffers were prepared at pH 4.0, 5.0,
6.0, 7.0, and 7.8 by mixing appropriate volumes of
0.1 M citric acid and 0.2 M disodium phosphate
solutions. SLS was dissolved with the buffers at
the concentration of 0.5, 1.0, and 2.0 w/v%. The
media were deaerated by stirring under vacuum
prior to use.
Dissolution Experiments
The intrinsic dissolution rates of PX were deter-
mined using the rotating disk method. PX powder
(200 mg) was compressed to form a circular com-
pact in the rotating disk die at 1,000 lbs for 10
min using a hydraulic press (Fred Carver, Inc.,
Summit, NJ). The die containing the compact was
mounted onto a Plexiglass shaft attached to an
overhead synchronous motor (Cole-Parmer Scien-
tific, Niles, IL). The die was rotated at 50, 100,
and 200 rpm. The rotational speed was calibrated
with a digital tachometer (Cole-Parmer Scientific,
Niles, IL). The single face of the compact was ex-
posed to 150 mL of the dissolution medium in a
jacketed beaker circulated with water heated at
37 ± 1°C using a water bath circulator (Isotemp
Constant Temperature Circulator Model 8000,
Fisher Scientific, Pittsburgh, PA). The dissolution
media was continuously circulated through a flow
cell using a peristaltic pump (Masterflex, Cole-
Parmer Scientific, IL) in 8 mL/min. UV absor-
bance at 254 nm was recorded at 1- or 5-min in-
tervals using a UV spectrophotometer (Perkin-
Elmer, Lambda 3B). Dissolved amounts of PX
were maintained less than 10% of the solubility
over the entire experiments to ensure sink condi-
tion.
Solubility Experiments
An excess amount of PX powder (50–200mg) was
shaken in screw-capped vials containing 10 mL of
buffers in an orbital shaker water bath (LAB-
LINE Instruments, Inc., Melrose Park, IL) at
37°C. At suitable time intervals 0.8-mL samples
were collected. The samples were filtered through
0.45 mm membrane filters and diluted with the
appropriate amount of buffer. PX concentration in
the samples was assayed by the HPLC method
described in United States Pharmacopeia XXII.
RESULTS
Solubility–Time Profile
The dissolved amount of PX versus time profile
indicates a maximal value of solubility shown in
Figure 3. The maximal solubility was obtained
after 8 h in the entire pH range except at pH 7.0
and 7.8 without SLS where the peak occurred af-
ter 2 h. The color of the crystals remaining on the
bottom of the sample vial was white at the time
when the solubility reached the maximum value.
The color then gradually changed to yellow with
decreasing solubility. This color change suggests
a crystal form conversion from the original anhy-
drous form (white) to monohydrate (yellow).23,24
This type of phenomenon has been reported for
theophylline, cholesterol, caffeine, glutethimide,
and succinyl sulfathiazole.25 The maximal solu-
bility values are most likely to be the driving force
of dissolution and were 2–4 times higher than
the values measured after 24 or 48 h. It has been
also reported that the anhydrous form has faster
intestinal absorption than monohydrate after
oral administration.26 The maximal solubility
values were used for analysis in this report
(Table I).
Table I. Maximal Solubility (mg/mL) of Piroxicam
at Different pH and SLS Concentrations
pH
SLS Concentration (w/v %)
0 0.5 1.0 2.0
4.0 0.0320 0.178 0.265 0.497
5.0 0.0396 0.188 0.334 0.531
6.0 0.198 0.359 0.427 0.659
7.0 1.37 1.45 1.62 1.98
7.8 4.79 4.59 5.43 5.05
Figure 3. Solubility time profile of PX.
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Intrinsic Dissolution Rate
Figure 4 shows typical results of the dissolu-
tion experiments. The intrinsic dissolution rates
were calculated as a slope of the plot multiplied
by the volume of media (150 mL) divided by the
surface area of the compact (0.950 cm2) using lin-
ear regression assuming zero intercept. The ob-
tained intrinsic dissolution rates are listed in
Table II. The data are the average of tripli-
cated values ± the standard deviation while the
average of duplicated values were presented for
cases in the presence of SLS at pH 7.0 and 7.8.
Dissolution at pH 7.8 with 1.0% or 2.0% SLS was
not measured due to rapid disintegration of the
tablet.
DISCUSSION
Nonlinear Regression Analysis of Solubility
The total solubility increased with increasing pH
and SLS concentration, as expected. The mea-
sured solubility values were fitted to eq 6 by non-
linear regression analysis. Figure 5 illustrates
the fitted surface with the observed values as
functions of pH and SLS concentration (r2 4 0.98,
P < 0.001). The pKa value and the micellar solu-
bilization equilibrium coefficients (k* and k**)
were estimated to be 5.63±0.02, 348±77 L/mol,
and 0.0±1.5 L/mol, respectively. The estimated
pKa value agrees well with the reported pKa2
value of 5.46 determined in DMSO/water (1:100)
by a spectrophotometric method. The low k**
value indicates that the micellar solubilization of
ionized drug is negligible.
Nonlinear Regression Analysis of Intrinsic
Dissolution Rate
Similar to the solubility, the dissolution rate also
increased with increasing pH and SLS concentra-
tion. These enhancements in dissolution are well
agreed with corresponding solubility enhance-
ment. The dissolution data were fitted to eq 16
with the pKa and k* fixed at the estimated values
from nonlinear regression analysis of the solubil-
ity data. The k** value was assumed to be zero
based on the analysis of solubility data. Figure 6
shows the result of the nonlinear regression
analysis for the normalized dissolution rate (J/
v1/2) as functions of pH and SLS concentration (r2
4 0.86, P < 0.02). The fitted surface is similar to
that of the total solubility. In the pH range lower
than its pKa, a relatively large dissolution en-
hancement of up to 30-fold, was observed by the
addition of SLS. In the pH range higher than its
Table II. Intrinsic Dissolution Rate (J/v1/2; ×104 mg/cm2/s1/2/rad1/2)
of Piroxicam at Different pH and SLS Concentrations
pH
SLS concentration (w/v %)
0 0.5 1.0 2.0
4.0 0.201 ± 0.009 0.892 ± 0.076 1.30 ± 0.15 2.12 ± 0.26
5.0 0.234 ± 0.019 0.837 ± 0.115 1.29 ± 0.19 2.04 ± 0.25
6.0 1.01 ± 0.04 1.74 ± 0.29 2.95 ± 0.16 3.09 ± 0.43
7.0 6.47 ± 0.41 10.8 ± 1.1 12.1 ± 0.3 11.8 ± 0.3
7.8 19.8 ± 1.3 33.7 ± 6.3 a a
a Not measured due to disintegration of the disk.
Figure 4. Dissolution curves of PX from the rotation
disk at 50 rpm.
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pKa; however, a relatively small enhancement of
up to 3-fold was observed. Since the pH in duode-
num is around 5 and that in jejunum is 5–6 under
fed state , the absorption of piroxicam can be in-
creased by postprandial bile secretion. However,
Ishizaki et al.27reported that the extent of PX ab-
sorption in man was uninfluenced by food intake.
This is probably due to potentially good absorp-
tion of PX due to its high jejunum permeability
(Peff 4 (10.40 ± 5.93) × 10
−4 cm/s in humans)28
and relatively low dose number (Do 4 11) . The
estimated diffusivity values for species PX, PX−,
and [PX]micelle were (0.93 ± 0.35) × 10
−5, (1.42 ±
0.30) × 10−5 , and (0.59 ± 0.21) − 10−5 cm2/s, re-
spectively. The diffusivity value of PX agrees well
with a theoretical value of 0.86 × 10−5 cm2/s cal-
culated from the estimated molal volume.29 The
diffusivity of [PX]micelle was 1.7 time lower than
that of PX. This decrease in diffusivity is due to
the higher molecular weight of [PX]micelle com-
pared to that of the free solute.5 However, this
ratio is lower than the ratio of 9.0 observed for the
carbamazepine–SLS system.18 Thus for the PX–
SLS system the enhancement in the dissolution
rate is the result of the increase in total solubility
due to the pH change and solubilization. These
results suggest that the dissolution process in
vivo, while more complicated due to the more
complex and time-dependent environment, can be
captured in vitro. However, when establishing an
in vitro–in vivo correlation for a compound such
as piroxicam, care must be taken when selecting
the pH of the dissolution media and the hydrody-
namics in the dissolution flask. For example, if
the solubility of the drug in the dissolution media
versus in vivo solubility is under-estimated, then
the first derivative of the correlation between the
fraction absorbed versus fraction dissolved will
decrease with time. On the other hand, if the solu-
bility of the drug in the dissolution media versus
in vivo solubility is over-estimated, the first de-
rivative of the correlation between the fraction
absorbed versus fraction dissolved will increase
with time. Thus, the time course of dissolution
rates in vitro and in vivo will in general be differ-
ent and some curvature in the IVIVC should be
expected.
CONCLUSION
The dissolution rate and solubility of PX are well
estimated by a simple additive model for the ef-
fect of pH and surfactant. The total solubility of
PX is a sum of the values for the individual spe-
cies PX, PX−, and [PX]micelle. The proposed model
will be useful in predicting the dissolution and the
solubility of an ionizable water-insoluble drug as
functions of pH and surfactant. It also suggests
that in vitro– in vivo correlations will in general
show some curvature for BCS Class II drugs.1
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